FDA Approves Guardant Health’s Blood Test for Colon Cancer Screening

The FDA has approved Guardant Health’s Shield, a blood test designed to screen for colon cancer, marking a significant advancement in early cancer detection. Although not a replacement for colonoscopies, Shield is expected to improve screening rates for the second-leading cause of cancer deaths in the U.S.

YES!!!! 🙌🏾

FDA approves new blood test to screen for colon cancer – NBC News https://t.co/rbRyMPrRTJ

— Prof FTO 🇳🇬🇺🇸 (@DrOdedina) July 29, 2024

The test detects DNA from cancerous tumors in the bloodstream, with research showing it is 83% effective in identifying colorectal cancers, especially in later stages. While the test costs $895 out-of-pocket, FDA approval will likely lead to coverage by Medicare and private insurers, making it more accessible.

However, a positive Shield test requires confirmation via colonoscopy to verify the presence and progression of tumors. This approval follows the earlier, less-used Epigenomics’ Epi proColon test, and aims to address the low screening rates, particularly among adults in their 40s and 50s.

FDA Approves New Blood Test for Colon Cancer https://t.co/nWVNVt1zq4 via @epochtimes

— Legal Beagle🇺🇸💪🇺🇸 (@LegalBeagle_USA) July 29, 2024

The test could potentially increase the number of people getting screened, thereby reducing cancer incidence and mortality. The medical community views this development as a promising step towards more accessible and effective cancer screening methods.

Key Points:

i. The FDA approved Guardant Health’s Shield blood test for colon cancer screening, a significant development in cancer detection.

ii. Shield detects DNA from cancerous tumors in the bloodstream and is 83% effective, particularly for later-stage cancers.

iii. The test costs $895 out-of-pocket, but FDA approval may lead to coverage by Medicare and private insurers, increasing accessibility.

iv. A positive Shield test requires a follow-up colonoscopy to confirm the presence of cancer, as the test is not a definitive diagnosis.

v. Shield aims to improve screening rates, especially among adults in their 40s and 50s, and address the low overall screening rates for colorectal cancer..

Lap Fu Ip – Reprinted with permission of Whatfinger News